Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: October 28, 2025
Reporting Period: Third quarter ended September 30, 2025
Context: The filing announces the financial results for the third quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references the announcement of financial results but does not contain the specific numerical data within the body of this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial figures are located in Exhibit 99.1 (Press Release), which is referenced but not included in the input content.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2025, have been announced.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These items are expected to be detailed in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net income, and cash flow figures for Q3 2025.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check the press release for any updates to full-year 2025 financial guidance.
- Confirm the status of key clinical trials or regulatory approvals mentioned in the full announcement.